Bioequivalence criteria for transdermal fentanyl generics: Do these need a relook?

Clinical Pharmacokinetics

Volumn 48, Issue 10, 2009, Pages 625-633

  Walter, Carmen ^a   Felden, Lisa ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DIAZEPAM; DIPHENHYDRAMINE; ESPARMA; FENTADOLON; FENTANYL; HEUMANN; KREWEL; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NORDAZEPAM; OXYCODONE; PARACETAMOL; PROMETHAZINE; RATIOPHARM; SANDOZ; TEMAZEPAM; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CANCER PAIN; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; EVENING DOSAGE; FEVER; HUMAN; MAXIMUM PLASMA CONCENTRATION; NOTE; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATION DEPRESSION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; DRUGS, GENERIC; FENTANYL; HUMANS; PRACTICE GUIDELINES AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 70349145732     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317200-000000000-00000     Document Type: Note

References (53)

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10 (4): 287-333
2. Lötsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6- glucuronide toxicity? Anesthesiology 2002; 97 (4): 814-819
3. Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004; 93 (2): 212-223
4. Brown DL. Postoperative analgesia following thoracotomy.Danger of delayed respiratory depression. Chest 1985; 88 (5): 779-780
5. Gerber N, Apseloff G. Death from a morphine infusion during a sickle cell crisis. J Pediatr 1993; 123 (2): 322-325
6. Goetz AM, Rogers PL, Schlichtig R, et al. Adult respiratory distress syndrome associated with epidural fentanyl infusion. Crit Care Med 1994; 22 (10): 1579-1583
7. Piquet CY, Mallaret MP, Lemoigne AH, et al. Respiratory depression following administration of intrathecal bupivacaine to an opioid-dependent patient. Ann Pharmacother 1998; 32 (6): 653-655
8. Byard RW, Gilbert JD. Narcotic administration and stenosing lesions of the upper airway - a potentially lethal combination. J Clin Forensic Med 2005; 12 (1): 29-31
9. Garriott JC, Di Maio VJ. Death in the dental chair: three drug fatalities in dental patients. J Toxicol Clin Toxicol 1982; 19 (9): 987-995
10. Lötsch J, Dudziak R, Freynhagen R, et al. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet 2006; 45 (11): 1051-1060
11. Gharagozlou P, Demirci H, David Clark J, et al. Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 2003; 3 (1): 1-8
12. Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64 (3): 527-534
13. International Narcotics Control Board. Statistical information on narcotic drugs. New York: United Nations Publication, 2006
14. UK NHS Information Centre. Prescription cost analysis: England 2007 [online]. Available from URL: http://www.ic.nhs.uk/statistics-and-data- collections/ primary-care/prescriptions/prescription-cost-analysis-2007 [Accessed 2009 Sep 4]
15. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2008: Aktuelle Daten, Kosten, Trends und Kommentare. Berlin: Springer, 2008: 232-237
16. Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic): seven case reports. J Forensic Sci 2008; 53 (1): 222-225
17. Kuhlman Jr JJ,McCaulley R, Valouch TJ, et al. Fentanyl use,misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol 2003; 27 (7): 499-504
18. Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004). J Anal Toxicol 2006; 30 (8): 603-610
19. Regnard C, Pelham A. Severe respiratory depression and sedation with transdermal fentanyl: four case studies. Palliat Med 2003; 17 (8): 714-716
20. Newshan G. Heat-related toxicity with the fentanyl transdermal patch. J Pain Symptom Manage 1998; 16 (5): 277-278
21. Carter KA. Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm 2003; 60 (2): 191-192
22. Frolich MA, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 2001; 93 (3): 647-648
23. Ortho-Mc-Neal-Janssen Pharmaceuticals. Duragesic®: full prescribing information [online]. Available from URL: http://www.duragesic.com/duragesic/ shared/pi/duragesic.pdf#zoom=100 [Accessed 2009 Aug 6]
24. Shafer SL, Varvel JR, Aziz N, et al. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology 1990; 73: 1091-1102
25. Mildh LH, Scheinin H, Kirvela OA. The concentration-effect relationship of the respiratory depressant effects of alfentanil and fentanyl. Anesth Analg 2001; 93 (4): 939-946
26. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81 (1): 50-58
27. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985; 62: 234-241
28. Hill HF, Chapman CR, Saeger LS, et al. Steady-state infusions of opioids in human: II. Concentration-effect relationships and therapeutic margins. Pain 1990; 43 (1): 69-79
29. Janssen-Cilag GmbH. Durogesic® SMAT: Fachinformation/prescribing information. Neuss: Janssen-Cilag GmbH, 2006
30. Fiset P, Cohane C, Browne S, et al. Biopharmaceutics of a new transdermal fentanyl device. Anesthesiology 1995; 83 (3): 459-469
31. Bleeker CP, Bremer RC, Dongelmans DA, et al. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur J Pain 2001; 5 (3): 325-39; discussion 329-331
32. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61 (15): 2289-2307
33. Marier JF, Lor M, Potvin D, et al. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006; 46 (6): 642-653
34. Voigt R. Pharmazeutische Technologie. 10th ed. Stuttgart: Deutscher Apotheker Verlag, 2006: 461-464
35. Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 1995; 6 Suppl. 3: 29-34
36. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70 (6): 928-934
37. Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 1991; 74 (1): 34-42
38. Marier JF, Lor M, Morin J, et al. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br J Clin Pharmacol 2007; 63 (1): 121-124
39. Henney JE. From the Food and Drug Administration: review of generic bioequivalence studies. JAMA 1999; 282 (21): 1995
40. Nwakama PE, Haidar SH, Yang YS, et al. Generic drug products demonstrate small differences in bioavailability relative to the brand name counterparts: a review of ANDAs approved 1996-2005. 12th Annual FDA Science Forum; 2006 Apr 18-20; Washington, DC
41. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240 (1): 159-166
42. McClain DA, Hug Jr CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28 (1): 106-114
43. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983; 8 (5): 422-446
44. Shafer SL, Varvel JR. Pharmacokinetics pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74: 53-63
45. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. DrugMetab Dispos 1997; 25 (9): 1072-1080
46. Lötsch J, Skarke C, Tegeder I, et al. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002; 41 (1): 31-57
47. Haberer JP, Schoeffler P, Couderc E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54 (12): 1267-1270
48. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17 (4): 746-752
49. Bentley JB, Borel JD, Nenad Jr RE, et al. Age and fentanyl pharmacokinetics. Anesth Analg 1982; 61 (12): 968-971
50. Luckenbill K, Thompson J, Middleton O, et al. Fentanyl postmortem redistribution: preliminary findings regarding the relationship among femoral blood and liver and heart tissue concentrations. J Anal Toxicol 2008; 32 (8): 639-643
51. Therapeutic Products Directorate, Health Canada. Guidance for industry. Bioequivalence requirements: critical dose drugs. Ottawa: Health Canada, 2006 Jun 7 [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/bio/critical-dose-critique-eng.php [Accessed 2009 Sep 4]
52. Thirstrup S. Bioequivalence and labelling of medicinal products with regard to generic substitution. Copenhagen: Danish Medicines Agency, 2005 Jul 13 [online]. Available from URL: http://www.dkma.dk/1024/visUKLSArtikel. asp?artikelID=6437 [Accessed 2009 Sep 4]
53. Bundesinstitut fur Arzneimittel und Medizinprodukte [BfArM]. Neues zur Aut-Idem Regelung: ist die Aut-idem-Regelung auch bei Schmerzpflastern anwendbar? Bonn: BfArM, 2008 [online]. Available from URL: http://www. bfarm.de/cln-028/nn-683944/SharedDocs/FAQ/DE/BtmGrundstoffeAMVV/ BtM/Rezepte/t2-verschr-ambul/ha-t2-BTMRezepte-faq8.html [Accessed 2009 Aug 17]